NCT07519356 A Comprehensive Register Of Lymphoproliferative Disorders (ReLy)
| NCT ID | NCT07519356 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia |
| Condition | Lymphoproliferative Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 9,000 participants |
| Start Date | 2022-06-09 |
| Primary Completion | 2030-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 9,000 participants in total. It began in 2022-06-09 with a primary completion date of 2030-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of this study is to assess the 10-year overall survival (OS) of patients with different lymphoproliferative disorders. Secondary objectives include evaluating the comorbidities and fitness of patients and their impact on treatment choices and outcomes. Additionally, the study will examine the effectiveness of various therapeutic regimens, with a particular focus on new treatments, such as chemo-free protocols, targeted drugs, and cell therapies, in order to determine the best treatment sequence for refractory and relapsed cases. The research will also investigate how clinical and biological factors influence disease progression or relapse. Another aim is to explore potential correlations between genotype, clinical phenotype, and outcomes, both at diagnosis and during various disease stages. The study will also assess the incidence of tumor lysis syndrome and other adverse events during treatment, considering how these factors might affect treatment discontinuations or dose reductions. Another objective is to evaluate the outcomes of patients who are managed with a "watch and wait" approach. Long-term toxicities and the occurrence of secondary malignancies will also be studied, alongside the analysis of healthcare costs and the resources used in patient management.
Eligibility Criteria
Inclusion Criteria: * Patients ≥ 18 years diagnosed with and/or treated for lymphoproliferative disorders. * Prospective patients (or their or legal guardians) who have the ability to understand and be willing to sign a written informed consent document * Retrospective patients who have signed the institutional document allowing the use of their data for research on their disease Exclusion Criteria: * Patients who are unable to understand informed consent document
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07519356 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoproliferative Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07519356 currently recruiting?
Yes, NCT07519356 is actively recruiting participants. Contact the research team at l.arcaini@smatteo.pv.it for enrollment information.
Where is the NCT07519356 trial being conducted?
This trial is being conducted at Pavia, Italy.
Who is sponsoring the NCT07519356 clinical trial?
NCT07519356 is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia. The trial plans to enroll 9,000 participants.